In a 2013 report, Sun et al. [18] demonstrated that a preoperative CTC count of ≥2 CTCs/7.5 mL predicted tumor recurrence after surgery in 123 HCC patients, especially in patients with AFP levels ≤400 ng/mL or low tumor recurrence risk. This evidence concerns the gene AFP and hepatocellular carcinoma.